Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very possible.
This can see the <7's today. The steam is running out.
aaand back down
I agree. They usually fall back to $3 or lower.
Wainwright is the worst.
$9.00 break
whatta solid rebound $HOTH 5-8's
when I usually buy a stock and it has an offering I usually get tortured for days as it sinks lower and lower
Not this time HOTH up now 8.00
Or maybe much lower, as it happens in similar situations. We have a bunch of examples where placements destroyed the price for long time.
And this $10 millions placement constitutes 77% of company's market capitalisation! Very heavy burden for a small company.
Ouch. Those bio pumps can kick you in the butt with those post run offerings.
Huge dump today back to $5 gap.
HOTH just another POS P&D IMO.
Good luck.
Sickening to see a stock do a placement that is 50% less than the last traded price.
I understand the company needs to raise capital, but it doesn't change the bad feeling from it all.
$HOTH: For someone pumping a Constantescu STOCK.............
Like Camber ENERGY that is a piece of crappppppppppppp................
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170804877
This is the wrong place for you too be.
Those douches won't even save you there anymore. Too bad you missed the MEGA run
here, and no...... ATLAS trading is ALL IN JAIL NOW !!!!!!!!!!
THAT is what you call a Pump & Dump lil girl.................
GO $HOTH
HOTH NICE ONE makin, PK*PH GOING ALSO !!,
$11.64 then $12.73 zones to watch
Float this tiny. Wonder how high this can go
$HOTH: Gonna rip over $12 here again shortly...........
Bigggggggggggggggggg DADDY CANE here
GO $HOTH
$HOTH: HALTED at 9.85.................. WOOOOooooooooooooooooooooo
HOLLA
Look at her rippppppppp
GO $HOTH
$HOTH: En fuegooooooooooooooo.... now 8.60
5 fire alarm .................. BOOYAKASHAAAAAAAAAAAAA
GO $HOTH
$HOTH: FDA Acceptance of IND-Applications are the HOT-chick in TOWN
Seen a few of these kinda headliners zoom off lately.
Keep your eyes peeled for this kinda headline next time going forward.
$HEPA could be on to watch for
GO $HOTH
$HOTH: DAMN now $7.70........ BOOOOMMMMMMMMMMMmm
Whatta a killer move from 4.20 just 30mins ago
Damnnnnnnnnnnnnnn nice
GO $HOTH
HOTH: Some Cancer drug NEWS this morning pushing it UP big in pre-market.
Meanwhile they dilute on this news..shady!
But, The Company is considering scheduling a special meeting of shareholders to reconsider the Reverse Stock Split proposal and will provide information to its shareholders, when available.
The last recent rise and fall was due to to current investors taking profits because they were afraid of losing I’ll gotten gains . There was some day trading as well. So instead of letting it run like bingo sbfm up to 10 dollars . They killed it from the start. They should give the company some credit for throwing them a bone.
Agreed. Worthless.
Well the offer is at the current market price. The problem with this stock is the negativity. The market movers and investor drives the stock up and down. If you play for short gains then the stock will never meet your expectation. They have the product and now they have the means. Let’s see what they can do.
Lol that's a base for meth and coke . Hmmmm wonder if that's why it is eleagle.
Has potential . That is evident with the stock offer. The details will be disclosed soon. Outside interest brings inside interest. Do your own DD and make your own decisions.
Yet MORE Petri-Dish-&-Test-Tube (so-called) science!! Heck, (Home Depot) ACETONE kills every single death-causing CANCER, MICROBE, etc., in a PETRI DISH or TEST TUBE as well!!! So, why not INJECT pure (Home Depot) ACETONE into Humans to treat the Covids, the Cancers, & EVERYTHING that afflicts Mankind????? (HA-HA-HA!!!
HOTH was --- and still is --- a SUCKERS' BATE MORNING GAPPER all day long, Bill! Hope YOU didn't buy some!
Insane volume, traders pushing this up, then down, then back up again. Long term, wish this company the greatest success with their HT-KIT therapy. Hopefully it can demonstrate an application for AML, a nasty, aggressive type of leukemia./ok2
This will explode today,,,, the number of people on Stocktwits is a pretty good indicator.
BONZAII AKTIVASION
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells
8:05 am ET April 11, 2022 (PR Newswire) Print
Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours
HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model.
Orphan Drug status granted, successfully completed API manufacturing feasibility
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced a development updates for its novel cancer therapeutic, HT-KIT.
https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg
Hoth's innovative approach, which employs a chemically-stable antisense oligonucleotide to target the proto-oncogene KIT through by frameshifting KIT mRNA transcripts, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated malignancies.
Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro and found that KIT protein expression, signaling and function were reduced. Treatment with HT-KIT prevented cancer cell growth and induced cell death over 72 hours. In a humanized mast cell leukemia mouse model, tumor growth and infiltration of other organs were reduced and tumor cell death increased when HT-KIT induced frameshifted c-KIT mRNA.
Hoth has filed several patent applications to protect this IP throughout the world.
"With our HT-KIT drug, we are flipping off a key cancer signal that's involved in multiple aggressive cancers, such as systemic mastocytosis, mast cell leukemia, gastrointestinal stromal tumors and acute myeloid leukemia. Our approach avoids pitfalls related to KIT mutations by targeting mRNA. Our next round of preclinical studies are underway and we are excited to utilize the results for our planned Pre-IND meeting with FDA later this year," stated Robb Knie, Chief Executive Officer of Hoth.
HT-KIT, a new molecular entity, was designated as an Orphan Drug for the treatment of mastocytosis earlier in 2022. HT-KIT Hoth has successfully completed manufacturing feasibility of the HT-KIT drug substance in collaboration with WuXi STA.
FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity.
About HT-KIT
HT-KIT is a new molecular entity (NME) under development for treatment of mast cell derived cancers and anaphylaxis. HT-KIT was developed Dr. Glenn Cruse, Assistant Professor at North Carolina State University and shares the same molecular class as Hoth's current HT-004 drug. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:LR Advisors LLCEmail: investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791
https://c212.net/c/img/favicon.png?sn=NY20869&sd=2022-04-11
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-mrna-frame-shifting-therapeutic-ht-kit-proves-effective-against-aggressive-cancer-cells-301522484.html
SOURCE Hoth Therapeutics, Inc.
https://rt.prnewswire.com/rt.gif?
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
303
|
Created
|
02/15/19
|
Type
|
Free
|
Moderators |
HaloVax, LLC is a biopharmaceutical company and joint venture entity of Voltron Therapeutics, Inc. and Hoth Therapeutics, Inc.
The joint venture was announced on March 23, 2020 (click here) and plans to advance an application of VaxCelerate,
a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH),
to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.
HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19.
The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents.
The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense (DoD).
These same principles are being applied to developing a vaccine against the COVID-19 pandemic.
VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting.
VaxCelerate offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens.
The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.
VaxCelerate was created by Drs. Mark Poznansky, MD, PhD, and Jeffrey Gelfand, MD,
who will continue to support its research and development, as COVID-19 has reached pandemic status. Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC)
and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific
advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting as well as to help gather additional academic and clinical KOLs to serve on the SAB.
Our goal: Generate a safe and effective vaccine with animal data in 6 months or less.
HaloVax is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccine (SAV) to patients at risk for COVID-19 infection.
We believe that our vaccine could be particularly effective and improve patient outcomes by engaging the immune system to identify and attack this pandemic infectious agent.
This technology has initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease.
This was done with the support of the DoD.
These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19
The SAV program has intellectual property surrounding composition of matter.
Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc.
The vaccine is >90% HSP70 and Aviden. Neoantigens are then incorporated to customize the vaccine.
We believe that the VaxCelerate technology has the potential to provide a differentiated approach to a COVID-19 vaccine.
Shs Outstand | 10.25M |
Shs Float | 8.33M |
Short Float | 3.18% |
Debt/Eq no debt | 0.00 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |